BIMZELX (UCB Pharma (division of UCB Australia Pty Ltd))
Product name
BIMZELX
Date registered
Evaluation commenced
Decision date
Approval time
216 (255 working days)
Active ingredients
bimekizumab
Registration type
NCE/NBE
Indication
BIMZELX (solution for injection) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.